Results 71 to 80 of about 262 (112)

Gastric perforation after duodenopancreatectomy. [PDF]

open access: yesMed Mycol Case Rep, 2017
Bäcker H   +3 more
europepmc   +1 more source

In vitro antifungal susceptibilities of six antifungal drugs against clinical Candida glabrata isolates according to EUCAST. [PDF]

open access: yesCurr Med Mycol, 2020
Fatahinia M   +4 more
europepmc   +1 more source

Second allogeneic transplantation in relapsed acute leukemia - a risk worth taking? [PDF]

open access: yesAnn Hematol
Zielińska P   +12 more
europepmc   +1 more source

[Management of side effects of CAR T cells]. [PDF]

open access: yesInn Med (Heidelb)
Bach F   +3 more
europepmc   +1 more source

[Visual diagnosis for experts]. [PDF]

open access: yesMed Klin Intensivmed Notfmed
Arheilger L   +6 more
europepmc   +1 more source

Mucormycosis, COVID-19 and Acute Lymphoid Leukemia: Case Report

open access: yes, 2021
Cordero-Hernández EL   +5 more
europepmc   +1 more source

Therapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in Adult People with Cystic Fibrosis. [PDF]

open access: yesJ Pers Med
Naehrig S   +12 more
europepmc   +1 more source

Posaconazole

Drugs of Today, 2005
Invasive fungal infections are occurring with increasing frequency secondary to medical advances in the areas of transplantation, cancer management and autoimmune diseases. Unfortunately, the currently available antifungal armamentarium does not meet the increasing needs of managing infection in these complex patient populations.
Elizabeth S, Dodds Ashley   +1 more
openaire   +4 more sources

Safety of posaconazole

Expert Opinion on Drug Safety, 2013
The increasing number of invasive fungal infections (IFI) among immunocompromised hosts is a significant clinical issue. Diagnosis of IFI, choosing among the available antifungal drugs, and the high morbidity/mortality associated with IFI pose clinical challenges for healthcare providers.
Pauline L, Jacinto   +1 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy